Should I Stay or Should I Go?

Slides:

Advertisements

Similar presentations

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.

Advertisements

FREEDOMS II TRIAL.

An Analysis of Monthly Surveillance 3T MRI in MS patients switched from long term natalizumab to teriflunomide in a controlled, prospective study K. Edwards,

NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: Results from the OPERA I and OPERA II, phase III studies G.

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

Multiple sclerosis: Oral Therapies and Beyond

The Nurse’s Role in Inflammatory Bowel Disease

Figure 1 An example of individual prediction of response to interferon β-1a and natalizumab in moderately advanced, active multiple sclerosis. Six treatment.

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

Highlights From the 2017 Annual European MS Meeting

Perspectives on Key MS Data From the Annual European MS Meeting

MS Highlights From the 2017 Annual Neurology Meeting

Program Goals Teriflunomide: Pooled Safety Data.

Challenges in the Diagnosis of MS: Physician and Nurse Perspectives

Immune Reconstitution in MS:

What Predicts Disability Progression in Multiple Sclerosis?

Current Controversies in Multiple Sclerosis Management

Charting Progress in MS Diagnosis and Treatment for Today and Tomorrow

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

Staying on Course: Optimizing Antiepileptic Medication Regimens

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

7.1b. Contrast coronal T1 Wtd MRI 7.1c. Contrast sagittal T1 Wtd MRI

When Would You Use Single Inhaler Triple Therapy in COPD?

Precision Management of RA and Comorbidities

Patient-Centric Approach to the Management of Spasticity

Patient Stories: Transitioning to Oral Prostacyclin Pathway Therapy

Talking to Patients About Diabetes Management

Clinical Updates in RA: New Developments and Insights From Washington

Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

Are We Closer to Personalized Medicine in MS?

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

التعلم بالإكتشاف المراجع:

Reversal Strategies for VKA: Truths and Misconceptions

Program Goals Disclaimer Overview Assessing Disease Activity.

Expert Debate in MDD.

Charting Progress in MS Treatment:

Poor Response to Initial Therapy for Migraine

Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis.

Introduction. Exploring Strategies for Recognition and Management of Lower Limb Spasticity in Children.

Treating to Target in MS

Managing Polycythemia Vera in the Community Setting

Case Study 56-year-old Presents With 1 Year of Worsening Dyspnea

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Program Goals Overview Is NEDA a Reasonable Target?

Tackling Schizophrenia With Your Patients

Pediatric Multiple Sclerosis: The Dawn of a New Era?

Clinical Pearls on Hot Topics in MS

Figure 1 ERG peak time delay at baseline

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.

Critical Decision Points in Insomnia

Pregnancy in MS.

A New Era of Renal Denervation Trials for Patients With Hypertension?

The Patient With Early Stage MF-CTCL

When Good Isn't Good Enough

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Program Goals Overview Is NEDA a Reasonable Target?

Oral Therapies in MS.

Mitigating Infection Risk With DMT in MS

MS, Age, and Immune Function

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.

Evaluating the Efficacy and Safety of Transitioning Patients from Natalizumab to Ocrelizumab (OCTAVE) Kyle Smoot, MD, FAAN1, Kiren Kresa-Reahl, MD1, Pavle.

Understanding the Role of Disability in MS Management

The Changing Face of Multiple Sclerosis: What Are the Experts Looking Forward To?

Impact of approaches for clinical and radiological monitoring on predicting of short-term and long-term disability outcomes in multiple sclerosis Brian.

Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis The rate.

Presentation transcript:

Should I Stay or Should I Go?

Program Goals

Initiating Therapy

Predicting DMT Response

Therapeutic Selection

Prognostic Factors

NTZ: An Aggressive DMT

Rebound Effects When Switching DMTs

Defining Induction Therapies

Discussing DMTs With Patients

Natural Course of MS

Shared Decision Making

Brain Volume Loss

Adverse Events

Defining Inadequate Response

Breakthrough Disease Activity

Subclinical Disease Activity and NEDA

Deconditioning and Disability

Addressing Cognitive Changes

MRI Measures in MS

Switching Therapies in MS

NTZ and New MRI Lesions

Switching From NTZ

Switching Oral Therapies

Conclusions

Abbreviations